Navigation Links
MET protein levels show promise as biomarker for aggressive colon cancer
Date:6/4/2013

HOUSTON - MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.

The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on survival, were released today at the annual meeting of the American Society of Clinical Oncology.

"When the epithelial cells that line the colon become cancerous, some of them develop special features to allow migration, causing the cancer to be more aggressive," said Kanwal Pratap Singh Raghav, M.D., fellow in MD Anderson's Division of Cancer Medicine. "Although EMT is a dominant molecular subtype, a biomarker suitable for clinical use has not been found. This research gives us an important step toward learning more about treating this colorectal cancer subtype."

In a bigger picture view, the study provides another piece of the puzzle of personalized cancer diagnosis and treatment.

"While we know there are many of types of colorectal cancer, we're not as advanced as we'd like to be in our understanding of them," said Scott Kopetz, M.D., Ph.D., associate professor in MD Anderson's Department of Gastrointestinal Medical Oncology and senior author of the study. "One of the larger goals of our research is to classify simple biomarkers that can be used by doctors in the community to identify subtypes. We want to condense sophisticated gene signatures down to single markers and simple tests that can be used to guide therapy."

The data were tested with:

  • Mann-Whitney U-test and Spearman rank correlation to determine association between MET protein expression and protein/gene expression of EMT markers and EMT gene signature scores
  • Regression tree method and Kaplan-Meier estimates to assess overall survival

Results of the analysis showed higher MET levels were found more often in colon tumors than rectal tumors.

Overexpression of MET was associated with:

  • Decreased overall survival
  • Higher gene expression of 28 EMT markers
  • Higher gene scores derived from three published EMT gene signatures

The researchers also determined that MET protein expression did not correlate with MET gene expression.

Next steps

Going forward, the group plans to apply this approach to other colorectal cancer subtypes, hopefully defining other simple and readily available biomarkers.

"The ultimate success in targeting colorectal cancer requires understanding molecular subsets of the disease," Kopetz said. "If we can identify and group cancers with similar behaviors, we'll be closer to identifying vulnerabilities and optimal therapies for each subset."


'/>"/>

Contact: Laura Sussman
sussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Researchers gain insight into key protein linked to cancers, neurodegenerative disorders
2. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
3. German and Israeli scientists gain new insights into protein disposal
4. Proteins in migration
5. Preclinical tests shows agent stops slippery proteins from binding, causing Ewing sarcoma
6. Study IDs key protein for cell death
7. Tumor-activated protein promotes cancer spread
8. Cancer drug prevents build-up of toxic brain protein
9. Amplification of a Stat5 gene produces excess oncogenic protein that drives prostate cancer spread
10. Can High-Protein, Low-Carb Diet Boost Fertility Treatment?
11. Assembly of a protein degradation machine could lead to treatments in cancer, neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: